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Abstract: DNA damage-inducing therapies are of tremendous value for cancer treatment and
function by the direct or indirect formation of DNA lesions and subsequent inhibition of cellular
proliferation. Of central importance in the cellular response to therapy-induced DNA damage is the
DNA damage response (DDR), a protein network guiding both DNA damage repair and the induction
of cancer-eradicating mechanisms such as apoptosis. A detailed understanding of DNA damage
induction and the DDR has greatly improved our knowledge of the classical DNA damage-inducing
therapies, radiotherapy and cytotoxic chemotherapy, and has paved the way for rational improvement
of these treatments. Moreover, compounds targeting specific DDR proteins, selectively impairing
DNA damage repair in cancer cells, form a promising novel therapy class that is now entering the
clinic. In this review, we give an overview of the current state and ongoing developments, and discuss
potential avenues for improvement for DNA damage-inducing therapies, with a central focus on the
role of the DDR in therapy response, toxicity and resistance. Furthermore, we describe the relevance
of using combination regimens containing DNA damage-inducing therapies and how they can be
utilized to potentiate other anticancer strategies such as immunotherapy.
Keywords: DNA damage-inducing therapies; cancer therapy; DNA damage response; DNA repair;
radiotherapy; cytotoxic chemotherapy; DDR modulators; combination therapies
1. Introduction
In the clinical landscape of anticancer strategies, DNA damage-inducing therapies have held a
prominent position for decades. This is emphasized by the fact that two of the main pillars of cancer
treatment, chemotherapy and radiotherapy, exert their anticancer activity by directly or indirectly
inducing DNA damage. Apart from these classical therapies, more targeted approaches such as
inhibitors of DNA damage-counteracting enzymes are now also entering the clinic [1]. The underlying
success of DNA damage-inducing therapies is the rationale that cancer cells respond to DNA damage
in a coordinated manner and, under suitable pharmacological conditions, can elicit a variety of
responses such as inhibition of cancer cell proliferation and induction of cell death. Alternatively,
the induced DNA damage can be repaired in a tightly controlled fashion, counteracting the effects of
DNA damage-inducing therapies and possibly even leading to therapy resistance. The induction of
DNA damage repair and cellular fates such as proliferation inhibition are orchestrated by a heavily
regulated network of proteins, collectively called the DNA damage response (DDR) [2]. Both healthy
and cancer cells employ the DDR as a protection mechanism as their DNA is constantly challenged
by endogenous- [e.g., reactive oxygen species (ROS)] and exogenous [e.g., ultraviolet (UV) radiation]
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sources [3]. With regard to therapy-induced DNA damage in cancer cells, DDR pathways thus play
a central role in tumor cell responses to DNA damage-inducing therapies as both protective and
target mechanisms. Although these therapies induce DNA damage in both healthy and cancer cells,
cancer cells are preferentially targeted due to specific alterations in their DDR pathways, leading to
genome instability [4]. This can have far-reaching effects on cellular behavior, such as an increase in
proliferation rate and impaired DNA repair as compared to healthy cells. Consequently, DNA damage,
resulting in detrimental cellular fates such as apoptosis, preferentially affects cancer cells.
The field of DNA damage-inducing therapies has seen a tremendous improvement in impact over
the last decades [5]. Since the discovery of the anticancer properties of radiotherapy and chemotherapy,
a large amount of knowledge was gained on their mechanism of action and clinical effects in different
patient groups [6,7]. Detailed insights into the specific components of the DDR that are activated by
therapy have resulted in the development of novel treatment opportunities. Furthermore, a better
understanding of toxicity and resistance on a molecular, cellular and tissue-level has led to significant
therapy refinement [8,9]. Ultimately, the goal of this research is to improve the therapeutic window,
defined as the range of drug dosing between the minimal dose for anti-cancer activity and maximum
dose for acceptable toxicity. Prompted by these developments, this review gives a broad overview of
the currently applied DNA damage-inducing therapies applied in the clinic and their mechanisms of
action, with a central focus on the importance of the DDR in therapy response and resistance. Moreover,
it will describe how this knowledge is used to further improve anticancer treatment among other
rapidly evolving fields such as immunotherapy.
2. The DNA Damage Response
As stated above, the role of the DDR for DNA damage-inducing therapies is crucial, as it can
counteract therapy effects, but can also be targeted by specific drugs. Therefore, a detailed understanding
of the various types of DNA lesions and the dynamics of the specific molecular pathways that they
activate is necessary to understand and improve therapy. The following sections will give an overview
of the major types of DNA lesions, as well as the corresponding DNA repair pathways.
2.1. Types of DNA Damage
Various types of DNA lesions can be induced endogenously, either directly or as intermediate
structures of repair processes for other lesions, or by external factors such as ionizing radiation (IR) or
chemicals (Figure 1B) [10]. First of all, single-strand breaks (SSBs) and double-strand breaks (DSBs)
arise from discontinuities in a single DNA strand or both strands, respectively. DSBs are a detrimental
form of DNA damage, as even a single DSB is capable of inducing cell death, and their induction
and processing can be highly mutagenic and have far-reaching consequences for the genome [11,12].
Importantly, DSBs can also form during cell division, when a replication fork encounters a SSB or a
blocking DNA lesion [13]. Furthermore, a wide variety of base and deoxyribose modifications can
be introduced, such as abasic sites, formed by the hydrolytic cleavage of a base from a deoxyribose
moiety. Additionally, several changes can be made to the base moiety itself, such as deamination,
alkylation and the formation of thymine dimers by UV rays [10,14,15]. Moreover, oxidative base
or deoxyribose damage can be induced, mainly by reactive oxygen species (ROS), which can either
be formed endogenously or as a byproduct from external agents. Other DNA damaging factors
can introduce covalent bonds between adjacent nucleotides on either the same or opposing DNA
strand(s), termed intrastrand and interstrand crosslinks (ICLs), respectively [16]. Finally, erroneous
base incorporation can occur endogenously during DNA replication or can be induced by external
agents, leading to base mismatches that distort the DNA helix structure [10].
2.2. DNA Damage Repair Pathways
An overview of the general signaling of the DDR is visualized in Figure 1A. Components of
the DDR regulate detection, signal transduction and repair upon damage induction and mediate cell
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cycle progression. After sensor proteins detect DNA damage, cell cycle checkpoints can be activated
to halt progression of proliferation and allow time for repair [17]. Recruitment of signal transducer
proteins mediates the subsequent activation of cellular repair cascades [2]. However, if DNA repair is
unsuccessful or the amount of damage exceeds a certain threshold, this can result in various detrimental
cellular fates [18]. These include programmed cell death (apoptosis), stable cellular growth arrest
(senescence) and cell death after inappropriate cell division (mitotic catastrophe).
Each type of DNA lesion requires a specific form of repair, performed by different
cross-communicating protein cascades. The various repair pathways, along with the specific DNA
damage types that activate them, are visualized in Figure 1B. Base excision repair (BER) is the dominating
pathway to repair SSBs and base lesions that do not significantly distort the DNA helix structure
(reviewed in [19]). General steps of this pathway include flipping out and cleavage of the damaged
base, incision of the nucleotide backbone at the resulting abasic site, DNA end processing, and refilling
the resulting gap by polymerases followed by ligation. In contrast, lesions that do significantly distort
the helix, including thymine dimers and intrastrand crosslinks, are repaired through the nucleotide
excision repair (NER) pathway (reviewed in [20]). After detection of these lesions, a single-strand
DNA segment around the lesion is removed, after which the remaining single-strand DNA is used as a
template for DNA synthesis by polymerases. ICL repair can be mediated by the Fanconi anemia (FA)
pathway upon replication fork stalling and subsequent involvement of other repair proteins such as
structure-selective endonucleases [21] and those involved in DSB repair (reviewed in [16]). In addition,
recently an FA-independent pathway for ICL repair was identified, mediated by the DNA glycosylase
NEIL3 [22]. For DSBs a variety of repair cascades have been described (reviewed in [23]). The major
generally distinct pathways are homologous recombination (HR) and non-homologous end joining
(NHEJ). After damage recognition and end processing, the error-free HR pathway uses homologous
DNA on the intact sister chromatid as a template to resynthesize DNA such that the integrity of the
broken chromatid can be restored. The requirement of an accessible sister chromatid makes that HR is
only effective during the S and G2-phases of the cell cycle. Alternatively, NHEJ is available during all
cell cycle stages and involves direct ligation of broken DNA ends without a homologous DNA template.
This pathway might therefore result in repair-associated errors such as insertions or deletions. Finally,
when erroneous nucleotide incorporation during replication occurs, mismatch repair (MMR, reviewed
in [24]) detects a DNA strand containing a mismatched nucleotide. Consequently, the DNA is nicked,
excised and resynthesized and ligated using the complementary strand as a template.
Figure 1. Overview of the DNA damage response. (A) General overview of the DDR signaling
cascade upon DNA damage induction, either endogenously or by external agents. After damage
detection by sensor proteins, transducer proteins activate effector proteins that can elicit a variety of
cellular responses. Cell cycle checkpoints will be activated to halt proliferation and allow time for
(accurate) repair. However, the inability to repair the induced damage can also lead to induction of
detrimental cellular fates such as apoptosis. (B) Visualization of types of DNA damage that can be
induced, as well as the main pathways that are directly involved in their repair. Abbreviations: SSB:
single-strand break; DSB: double-strand break; FA pathway: Fanconi anemia pathway.
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3. DNA Damage-Inducing Therapies
3.1. Radiotherapy
Radiotherapy has been one of the cornerstones of cancer treatment for decades with currently over
50% of cancer patients worldwide receiving this therapy [25]. The most widely used form is external
beam radiotherapy (EBRT), which uses high-energy photons with a relatively high tissue penetration
depth [26]. EBRT is mainly carried out with a linear accelerator producing x-rays or a cobalt-60 source
producing γ-rays [27]. However, other forms of EBRT, especially those employing beams of charged
particles such as protons, are becoming increasingly important for cancer treatment [28]. In contrast
to EBRT, brachytherapy is practiced by placing the radiation source within the body, close to the
tumor [29]. Finally, systemic administration of a radionuclide is used during molecular radionuclide
therapy (MRT) [30]. Most research on cellular and physical effects of ionizing radiation (IR) have been
performed in the context of EBRT with photon radiation. As the nature of the induced DNA damage
is dependent on specific radiation characteristics, the results of this research can probably not be
extrapolated one on one to other types of radiation such as proton therapy and MRT. When comparing
these different types of radiation, the term relative biological effectiveness (RBE) is often used [31].
This is the ratio of the absorbed dose of a radiation type to the absorbed dose of a reference type that
induces the same biological endpoint, with x-rays with a defined energy or cobalt-60 γ-rays often used
as the reference radiation type. To exploit the full potential of all these forms of radiotherapy in the near
future, more radiobiological research in this area should result in the more accurate prediction of their
RBE values and elucidate how their anticancer effect differs from photon beam therapy mechanistically.
On a molecular level, the general effects of IR can be divided in direct and indirect effects (Figure 4).
Direct effects result from the physical induction of breaks and other DNA lesions, while indirect
effects include ROS formation from intracellular water molecules and subsequent free radical-driven
formation of lesions such as abasic sites and SSBs [32]. The BER, HR and NHEJ pathways of the
DDR are well-known to play an important role in the cellular response to IR-induced DNA damage.
Besides induction of the different single types of DNA damage, groups of multiple lesions in close
vicinity (within 1–2 DNA helix turns) have been detected in cells after IR treatment, collectively termed
clustered DNA damage [33,34]. These clusters consist of various lesion types, including DSBs, SSBs
and abasic sites. The formation of damage clusters is thought to be dependent on the linear energy
transfer (LET, defined as the amount of energy a particle disposes along its track per unit of distance)
of the IR type used, with higher LETs corresponding to induction of more complex DNA clusters [35].
Importantly, the complexity of DNA damage is suggested to have an effect on DNA repair efficiency.
As an example, DSB break termini at clustered DNA damage sites were shown to impair the removal
of base lesions by the BER machinery [36]. Findings like these imply that complex DNA damage might
contribute significantly to exceeding the cellular capabilities of DNA repair and forces cells towards
induction of cell fates such as apoptosis.
Of central importance for the cellular response to IR is the radiosensitivity of targeted cancer
cells. This crucial characteristic is influenced by multiple factors, both on a tissue and cellular
level. A well-known example of such a factor is tumor hypoxia, which increases radioresistance [37].
Another factor is the cell cycle phase of a cancer cell at the time of DNA damage induction. Cells in the
G2/M-phase of the cell cycle are the most radiosensitive, while cells in late S-phase tend to be the most
radioresistant [38]. Factors on a DDR-level can also have a significant effect on intrinsic cancer cell
radiosensitivity. The way different tumors, or even different cells within the same tumor, deal with
IR-induced DNA damage might significantly vary, depending on specific alterations in their DDR.
Demonstrating this concept, transfection of tumor cells from DSB repair-deficient mice with DSB repair
gene DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) increases tumor radioresistance
for EBRT [39]. In a more extreme case, mutations in the DSB repair gene ataxia telangiectasia mutated
(ATM) in the neurodegenerative disease ataxia telangiectasia (AT) leads to hypersensitivity to IR [40].
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These findings implicate that DDR alterations can be used as predictive biomarkers for the tumor
response to IR [41].
3.1.1. External Beam Radiotherapy
Treatment of patients with EBRT is done using a source outside the body and traditionally
multiple doses of IR (fractions) are administered over the course of the treatment [42]. This reduces
toxicity and allows critical cellular factors, such as cancer cell cycle phase, to redistribute between
fractions [26]. Photon beams are the most widely used type of EBRT and have shown good efficacy for
many cancer types. At the beginning of their track, when entering the body, they exhibit a high energy
deposition, which reduces along the path and thus local radiation dose decreases with penetration
depth (Figure 2A). For tumors located in deeper tissues, this energy deposition pattern might thus lead
to a relatively high radiation dose at the entrance site of the body. This toxicity in healthy tissues is a
well-known major drawback of EBRT [8]. However, by irradiating from different angles, a sufficient
dose to the tumor can be reached while keeping radiation exposure to the healthy tissues minimal.
Unfortunately, a wide variety of both early toxic effects, such as cell death in other highly proliferating
tissues than the tumor, and late toxic effects, such as tissue fibrosis, have been reported. To counteract
toxicity and improve therapy efficacy, the field of radiotherapy, especially photon therapy, has seen a
large amount of developments with regard to radiation sources, treatment planning and delivery [26].
Notably, these include alterations of the ratio of dose per exposure and exposure frequency, known as
hyper- or hypofractionation regimens.
Figure 2. Overview of DNA damage induction patterns as a function of tissue depth for two types
of EBRT, using either photon or proton beams. The induction of damage in superficial and deeper
tissues is visualized (upper panel), as well as the course of the relative dose with increasing tissue
depth (lower panel). (A) For photon beams, the highest dose will be deposited at the body entrance
site, corresponding with the highest density of induced DNA lesions. The local relative dose will
then decrease with increasing penetration depth in tissues. (B) For proton beams, the entrance dose is
relatively low, followed by a sharp peak (the Bragg peak) in deeper tissues. Correspondingly, induced
DNA damage will be most significant in these deeper tissues.
In addition to photon beams, particle-based beams are increasingly incorporated in treatment
schemes [28]. These beams, as opposed to γ-radiation, display an increasing energy deposition along
their track, leading to a higher biological effect in deeper tissue regions [43] (Figure 2B). A sharp
peak of the energy deposition occurs at the end of the particle track, termed the Bragg peak. Particle
beam-based treatment, such as proton beam therapy (PBT), therefore can be most effective in deeper
tumors, while sparing surrounding healthy tissue. It is suggested that PBT induces a high amount of
complex DNA damage at the Bragg peak, although the exact nature of this damage, the mechanism by
which this damage is induced and crucial repair pathways are not yet known [44]. When translating
photon to proton therapy planning schedules in the clinic, an RBE of 1.1 is applied to adjust proton
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therapy dosage [31]. However, the RBE can significantly differ along the proton beam path, with
important implications for therapy design [45]. This implies that more research into the exact effects of
proton therapy is still crucial for further adaptation in the clinic.
3.1.2. Brachytherapy
Brachytherapy is a form of internal radiotherapy where a radiation source (for example,
an encapsulated radionuclide) is placed inside the body, close to the tumor [29]. Therefore, this form of
therapy is mainly employed for patients with organ-confined cancer [46]. Brachytherapy has been used
to treat several types of cancer, including those of the breast, prostate and cervix [29]. The two main
methods are interstitial and intracavitary therapy [47,48]. During interstitial therapy, a radiation source
is placed directly within the target tissue which, for example, is often used for breast cancer treatment.
In contrast, intracavitary therapy includes placement of the source in close proximity to the target tissue,
such as a nearby cavity. An important determinant in brachytherapy is the dose rate: during high dose
rate (HDR) therapy, a radiation source, for example contained in a catheter, is placed inside the body
temporarily and delivers a high radiation dose in a short timeframe. Low dose rate therapy (LDR)
involves the permanent implantation of a source, often in the form of a seed. Currently, significant
research efforts are aimed towards best practices in dose rate in various cancers [46]. For low-risk
prostate cancer, for example, LDR brachytherapy has been utilized for years, but increasing data point
towards HDR therapy as a superior therapy choice due to its lower acute and chronic toxicity [49].
There are important differences between anticancer effects of EBRT and brachytherapy,
mainly based on the difference in distance between the radiation source and the tumor [29]. The center
of a solid tumor seems to be targeted much more effectively by brachytherapy. Furthermore, the close
proximity to the tumor of the radiation source leads to reduced toxicity in healthy tissues [50]. It is
likely that a different tumor response will be induced by brachytherapy compared to EBRT, in terms
of induced DNA damage and activated DDR components [51,52]. This difference will be highly
dependent on total applied dose and dose rate.
A relatively novel form of brachytherapy that is used for both primary and metastasized liver
cancer is radioembolization [53]. This therapy involves the intra-arterial administration of microspheres
containing a radionuclide, mostly yttrium-90, which will accumulate in intratumoral capillaries due
to their size distribution. The underlying rationale is that a relatively high radiation dose can be
targeted to the tumor selectively [54], as the main blood supply of the tumor occurs via the liver artery.
In contrast, blood supply for hepatocytes mainly occurs via the portal vein, limiting radiation exposure
to healthy liver tissue.
3.1.3. Molecular Radionuclide Therapy (MRT)
The principle of MRT relies on the systemic administration of a radioactive compound.
The radionuclide can either physiologically be translocated to the tumor or is coupled to a
tumor-targeting carrier small molecule, peptide or antibody, delivering a high radiation dose to
the tumor specifically [55]. This strategy enables effective targeting of (metastasized) tumors while
sparing healthy tissues. Nevertheless, hematological, renal and liver toxicities have been reported in
MRT [56].
Various radionuclides are currently being clinically evaluated for use in MRT. These radionuclides
emit different types of particles with varying energies, resulting in different LETs and penetration
ranges and holding important implications for their biological effects [57,58]. These forms of radiation
include α-particles, with a high LET and short range, inducing complex DSBs in close proximity to
the source [59,60]. In contrast, β-particles have a lower LET and longer range, inducing less complex
damage but enabling the targeting of larger tumors [58,61]. Finally, Auger electrons have a very short
range due to their relatively low energy [57,61]. However, as multiple Auger electrons are released
during radionuclide decay, they can exert a relatively high biological effect, inducing damage with
high complexity. Due to their short range, Auger-emitters should be present in a cell nucleus to directly
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induce DNA damage [62]. A visualization of the biological effects of α-emitters, β-emitters and Auger
electrons is depicted in Figure 3.
A classic example of MRT is the use of the β-emitter iodine-131, which is selectively taken up
in the thyroid and thus can be effectively targeted to thyroid cancer [63]. Furthermore, β-emitter
lutetium-177 coupled to the somatostatin analog octreotate is currently FDA and EMA-approved
for the treatment of metastasized gastroenteropancreatic neuroendocrine tumors by targeting the
overexpressed somatostatin receptor 2 [64]. In addition, of increasing importance is the coupling
of radionuclides to prostate specific membrane antigen targeting molecules to treat prostate cancer,
for which various research lines are currently ongoing towards a better toxicity profile and patient
response [65].
Research on differences in DNA damage induction and relevant DDR pathways between MRT
and EBRT is currently ongoing, with a major factor being the dose rate: while EBRT is applied as
an acute high dose, local IR delivery by radionuclides can last for several days to weeks, depending
on radionuclide half-life [66]. These features give important implications for our understanding of
MRT radiobiology and future research directions. Apart from investigating different radionuclides,
the current search for improvements includes testing other peptides or antibodies, identifying novel
tumor target molecules and using combination treatments to enhance therapy effect [67].
Figure 3. Visualization of DNA damage induction patterns of beta-emitters, alpha-emitters and Auger
electrons, ordered (from left to right) by decreasing penetration range and increasing complexity of
induced DNA damage. While beta-emitters exhibit a relatively long penetration range, they mostly
induce isolated lesions. Alpha-emitters have a shorter range, but can locally induce more complex
forms of DNA damage that are less readily repaired. Auger electrons display the shortest range of the
three, but due to the fact that multiple electrons are released from the radionuclide they can still induce
a high biological effect locally.
3.2. Cytotoxic Chemotherapy
Since the discovery of the anticancer properties of nitrogen mustards against lymphomas in the
1940s, many years of development in chemical biology have led to the widespread adaptation of
cytotoxic chemotherapeutics in oncology [6,68]. The central principle of chemotherapy relies on the
preferential targeting of highly proliferating cells by chemicals directly inducing DNA damage or
interfering with DNA-related processes such as replication [69]. Furthermore, some chemotherapeutics,
such as mitotic inhibitors, exert a mechanism of action that is not directly DNA-targeted. The five
main classes of DNA-targeting cytotoxic chemotherapy, grouped by their mechanism of action,
are alkylating agents, platinum-based compounds, antimetabolites, topoisomerase inhibitors and
antitumor antibiotics [69]. Their respective mechanism of action is visualized in Figure 4.
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Figure 4. Visualization of the DNA-targeted mechanisms of action of radiotherapy, cytotoxic chemotherapy and DDR modulators. 1. Ionizing radiation (IR) can
induce DNA damage both directly and indirectly (through ROS formation), leading to formation of SSBs, DSBs and different base lesions. Depending on the
radiation type used, clustered (complex) DNA damage might be induced when multiple DNA lesions are formed in close vicinity. 2. Alkylating and platinum-based
compounds harbor a reactive site and directly react with the DNA molecule., forming DNA adducts and intra- or interstrand crosslinks. 3. Antimetabolites mimic
molecules essential in DNA replication and repair and, depending on the specific compound, can be incorporated in the DNA leading to DNA damage. Alternatively.
antimetabolites can inhibit nucleotide producing pathways. 4. TOPI- and TOPII-poisons, the most clinically relevant topoisomerase inhibitors, trap topoisomerases
on the DNA, preventing re-ligation of topoisomerase-induced breaks. For TOP1 poisons, DSBs are formed when DNA polymerase stalls on this trapped complex.
However, for TOPII-poisons, trapping leads to the persistence of topoisomerase-induced DSBs. 5. Antitumor antibiotics can have different DNA-targeted mechanisms
of action, such as compound intercalation in the DNA and induction of ROS formation. Other antitumor antibiotic mechanisms of action overlap with other cytotoxic
chemotherapeutic classes, such as DNA alkylation and topoisomerase poisoning. 6. DDR modulators target specific DDR proteins and exert their cancer-inhibiting
effect by synthetic lethality: as cancer cells that have loss-of-function mutations in specific DDR pathways become more reliant on backup repair pathways, inhibition
of the latter by DDR modulators can specifically target cancer cells versus healthy cells.
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Cytotoxic chemotherapies preferentially target tumor cells based on their rapid proliferation,
as DNA damage induction and inability to repair this damage will be the most significant in these cells.
However, a well-known major drawback of commonly used chemotherapeutics is their unfavorable
toxicity profile, most profoundly in rapidly proliferating healthy tissues, with a wide variety of both
early and late side-effects reported upon treatment. These range from acute toxicities such as nausea to
more detrimental effects such as cardiotoxicity, bone marrow injury and the development of secondary
malignancies [70–72]. Furthermore, and similar to radiotherapy, intrinsic or acquired resistance to
chemotherapeutics remains a clinical challenge [9]. Resistance can occur on a macroscopic level, mainly
by unfavorable absorption, distribution, metabolism and excretion drug properties. Furthermore,
the cause of resistance can be on a molecular level, for example by altered transmembrane drug
transport (e.g., increased efflux), inactivation of cell death pathways and elevated pro-survival signaling
by oncogene activation or tumor suppressor gene inactivation [9]. Tumor-specific alterations of DDR
signaling also significantly contribute to drug resistance, especially when they occur in crucial repair
pathways for the DNA damage type induced by a given chemotherapeutic compound. For example,
levels of RAD51, a major HR mediator, positively correlated with resistance to the chemotherapeutic
etoposide in small cell lung cancer [73].
3.2.1. Alkylating Agents and Platinum-Based Compounds
Alkylating agents react directly with the oxygen and nitrogen atoms of DNA bases to form a variety
of adducts [74]. While monofunctional alkylating agents, such as temozolomide and dacarbazine, have
a single reaction site forming an adduct on one DNA strand, bifunctional agents, such as aziridines
and epoxides, can react with two strands simultaneously resulting in ICLs [75]. An important role
in alkylating agent DNA damage repair is attributed to the BER and NER pathways, as well as
to specific proteins that can directly remove the DNA adducts, mainly O-6-methylguanine-DNA
methyltransferases (MGMT). In addition, various other pathways play a role in the processing of
secondary lesions: MMR is activated upon DNA mispairing with an alkylated base and intermediate
structures that arise during the repair of drug-induced lesions, such as DSBs, are repaired by HR and
NHEJ [75,76].
Platinum-based compounds, such as cisplatin, carboplatin and oxaliplatin, exert a similar
mechanism of action as alkylating compounds. After entering the cell, the compounds undergo
hydrolysis, yielding a platinum-containing moiety with two DNA-reactive sites [77,78]. This process
enables the molecule to form intra- and interstrand crosslinks. A multitude of repair pathways play a
role in the removal of these DNA lesions [79]. Specifically, NER proteins are important in the removal
of intrastrand crosslinks, and the HR, NER and FA pathways contribute to the removal of ICLs in a
coordinated matter [80].
3.2.2. Antimetabolites
In contrast to direct DNA reacting agents, antimetabolites function by mimicking molecules
essential in DNA replication and repair [81]. These could either be compounds that inhibit
deoxynucleoside triphosphate (dNTP)-producing pathways, depleting DNA polymerases of required
nucleotides, or compounds that are incorporated in the DNA itself. Well-known examples are
nucleoside analogs such as 5-fluorouacil (5-FU), which can both inhibit the synthesis of the nucleoside
thymidine and, after metabolism of the drug into a nucleotide analog, can be incorporated in the
DNA [82]. Depletion of necessary dNTPs leads to ineffective DNA damage repair and replication
by termination of newly synthesized DNA segments [81]. Furthermore, incorporation of nucleotide
analogs in the DNA can lead to chain termination. However, depending on the compound, chain
elongation by DNA polymerases might be possible with the nucleotide analog erroneously incorporated.
All of these mechanisms can result in activation of the DDR. The stalling of replication forks upon
chain termination may lead to induction of SSBs, DSBs and other DNA lesions. Upon replication fork
stalling, the activation of HR seems to play a crucial role in the cellular response to antimetabolites [83].
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Alternatively, when nucleotide analogs are erroneously incorporated in the DNA, BER and MMR
pathways have been described to be important repair pathways [84]. It was suggested that HR is
also involved in the repair of intermediate structures during antimetabolite-induced BER and MMR
repair [85].
3.2.3. Topoisomerase Inhibitors
Topoisomerase inhibitors target topoisomerases, enzymes that counteract the over- or
underwinding of DNA, for example during DNA replication [86]. The two main classes of these drugs
are topoisomerase poisons, which stabilize the topoisomerase-DNA complex, and topoisomerase
catalytic inhibitors, which inhibit enzymatic activity of topoisomerases by other mechanisms, such
as preventing DNA binding [87]. Currently most clinically relevant topoisomerase inhibitors are
poisons, which have been found to exert the most potent anticancer activity. Topoisomerase poisons
act by binding protein-DNA complexes and trapping these complexes onto the DNA [88]. Type I
topoisomerases (TOPI) poisons, such as topotecan and irinotecan, create SSBs to exert their function,
while type II topoisomerase (TOPII), such as etoposide, create DSBs for this purpose. For TOPI-poisons,
DSBs are formed when the DNA polymerase stalls upon the topoisomerase-DNA complex during
replication [89]. While TOPII-induced DSBs are normally transient, binding of the topoisomerase-DNA
complex by TOPII-poisons blocks re-ligation of these breaks, leading to damage persistence [90].
In both cases, the formation of DSBs will lead to induction of cell death. Because TOPI-poisons induce
SSBs that can be converted into DSBs as a result from fork stalling during replication, both the BER
and HR machinery are important in the cellular response to these compounds [91,92]. However, as
TOPII-poisons induce DSBs throughout the cell cycle, HR and NHEJ can both be activated as a repair
pathway [93,94].
3.2.4. Antitumor Antibiotics
Antitumor antibiotics are a class of chemotherapeutics with various DNA-centered mechanisms of
actions, partially overlapping with the chemotherapeutic classes described above. The main difference
with the other chemotherapeutic classes is that antitumor antibiotics are derived from microbes such
as Streptomyces. Important classes of antibiotics used in cancer care include anthracyclines, mitomycin
C and bleomycin. Anthracyclines, with doxorubicin as a well-known example, both intercalate in the
DNA and function as a TOPII-poison [95,96]. Additionally, these compounds generate high levels of
ROS. However, the complete mechanism of action of doxorubicin is currently still unknown and a
variety of other anticancer mechanisms have been proposed [97]. In contrast, mitomycin C functions as
an alkylating compound by forming covalent linkages with the DNA [98]. Finally, bleomycins mimic
the effects of IR by generation of ROS and subsequent DNA damage induction [99]. For this reason,
these compounds are classified as a ‘radiomimetic’.
3.2.5. Improvement of Chemotherapy
Compared to other rapidly evolving fields such as targeted therapies and immunotherapy,
truly novel developments for cytotoxic chemotherapies are lagging behind. Few new cytotoxic
chemotherapeutic drugs have reached the clinic in the past few years, with trabectedin, an alkylating
compound that can interact with transcription, DNA repair and the tumor micro-environment, as
one of the examples [100]. Rather, developments of chemotherapeutics have focused on the design
of structural analogues of already approved compounds [69]. A good example is the design of
cisplatin analogues, such as carboplatin, to improve drug properties, especially with regard to toxicity
profiles [78]. Additionally, developments for cytotoxic chemotherapy include improved drug targeting
and delivery methods, such as the use of liposomes and other nanocarriers and the use of pro-drugs
that are activated by tumor-specific factors [101,102]. Furthermore, de-escalation of chemotherapeutic
treatment, lowering treatment intensity to a point where the same beneficial clinical effect can be
reached as when using the original dose, has gained a lot of attention for toxicity reduction [103].
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Finally, a very important development, as for the other therapies described in this review, is the use of
chemotherapeutics in combination regimens. This will be further explained below.
3.3. Targeted Therapies: Modulators of the DDR
While radiotherapy and cytotoxic chemotherapy target tumors through their relatively fast
proliferation rate, the field of oncology has been shifting towards a form of medicine where
tumor-specific factors can be targeted, leading to more favorable therapeutic windows [104].
These factors could be proteins that play a crucial role in the survival of tumor cells, while they
are less important in healthy cells. Given the important role of the DDR in the cellular response to
DNA damage and the fact that cancer cells often are genomically unstable and have inactivation of one
or more DDR pathways, the development of drugs targeting DDR proteins has received considerable
attention in the past few years [1]. These DDR modulators have been under investigation both as
monotherapies and in combination with other DNA damaging therapies.
In many cases, especially in a monotherapy setting, the rationale behind the development of these
DDR modulators is based on the concept of ‘synthetic lethality’: in cancer cells having loss-of-function
mutations in DDR genes, consequently impairing a certain DDR pathway, the pharmacological
inhibition of back-up pathways can lead to tumor-specific cell killing or proliferation inhibition [105].
Healthy cells that do not have this loss-of-function mutation are not dependent on these back-up
pathways and will be able to repair the corresponding type of DNA damage via the original pathway.
The textbook example of this concept is the inhibition of poly(ADP-ribose) polymerase (PARP) for
breast cancer gene 1/2 (BRCA1/2)-deficient tumors [106]. Its underlying principle is that BRCA1- or
BRCA2-deficiency leads to impaired HR in cancer cells, weakening the DSB repair capacity in these
cells specifically. PARP inhibitors block the function of PARP1, an enzyme crucial in SSB repair [107].
Unrepaired SSBs will be converted to one-ended DSBs during replication, which require HR for repair.
However, this is not possible due to the HR-deficiency of the cancer cells. In addition, PARP inhibitors
can physically trap PARP onto the DNA, forming an obstacle for the replication fork and leading to fork
stalling [108]. Collapse of stalled replication forks can consequently lead to additional DSB formation.
The accumulation of DSBs during S-phase by PARP inhibitor treatment, in combination with impaired
HR, results in a potent anticancer activity while healthy cells are not affected. Promising clinical results
demonstrating this concept ultimately led to the approval of four different PARP inhibitors (olaparib,
niraparib, rucaparib and talazoparib) for treatment of breast, ovarian and pancreatic cancer [109].
In addition to PARP inhibitors, several other DDR modulators are being evaluated. One of
the strategies that has made the most clinical progress is inhibition of ataxia telangiectasia and
Rad3-related (ATR) protein kinase, with currently several compounds in phase II clinical trials [110].
As a monotherapy, ATR inhibitors are effective in cancer cells with mutations in various proteins
involved in DSB repair, including ATM [111]. ATR is essential in the response to replication stress
and prevents the collapse of stalled replication forks, which would lead to DSB formation [112]. ATM
mediates the initiation of DSB repair and is a central player in the activation of cell cycle checkpoints.
Therefore, the proposed mechanism behind the synthetic lethal relationship between ATR and ATM is
that ATR inhibition increases the number of DSBs and tumor-specific loss-of-function mutations in
ATM impair the repair of these DSBs [113]. Similarly, synthetic lethal relationships of ATR and several
proteins involved in HR have been found [114]. In addition, a variety of other DDR modulators are in
clinical development and a vast amount of preclinical research currently focuses on the identification
of novel potential drug targets, aided by the use of high throughput synthetic lethality screens [115].
Crucial to the use of DDR modulators, both in a monotherapy and combinatorial context, is the
identification of patient-specific biomarkers. Detection tests should be able to accurately identify
cancer-specific mutations that can be targeted through a synthetic lethal approach. Constant technical
revolutions in patient stratification techniques such as next generation sequencing are resulting in
different test types that can now guide treatment decisions [116]. For example, for PARP inhibitors,
techniques identifying HR-deficient patients range from sequencing to functional ex vivo assays of
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DSB repair on tumor tissue [117]. Illustrating the need for patient stratification, BRACAnalysis CDx,
a sequencing-based test for BRCA1/2 mutations, has been FDA-approved as a companion diagnostic
for PARP inhibitor treatment [118].
Despite the effectiveness of DDR modulators against a range of cancers, multiple resistance
mechanisms have been reported. For PARP inhibitors, for example, these include increased drug efflux
and reactivating mutations in BRCA1/2 genes [119]. An important strategy to counteract resistance
could be the combination of DDR modulators with other DNA damage-inducing therapies, which will
be further described below.
4. Combination Approaches Involving DNA Damage-Inducing Therapies
The combination of different anticancer modalities is seen as an important future direction for cancer
treatment and this is also a significant area of interest for DNA damage-inducing therapies [120,121].
The use of combination treatments has several potential advantages over monotherapy application,
mainly increased anticancer efficacy and reduced toxicity. The latter can occur when two or more
drugs can be used at a lower concentration than when they would be administered as a monotherapy.
Moreover, if the used agents target different cellular pathways, development of acquired resistance can
be delayed or prevented.
Clinically relevant combination therapies can show an additive effect, where the effect of the
combination is merely the sum of the effects of the independent DNA damaging agents [122]. This occurs
when the components of a combination regimen induce two mechanistically separate forms of DNA
damage. However, ideally, the combination of two given agents is synergistic, where the effect of
multiple drugs combined is greater than the sum of their individual effects. Synergistic effects can
result from interactions between two or more drugs on multiple levels, including that of the DDR.
Importantly, to exploit the advantages of combination therapies, a rational method of combination
design is necessary, based on extensive knowledge of therapy mechanism of action including activated
DDR pathways.
In this section we will summarize the main combinatorial approaches for DNA damage-inducing
therapies, as well as combinations of those therapies with immunotherapy.
4.1. Radiotherapy and Chemotherapy Combinations
One of the oldest combination strategies in oncology is that of combining multiple cytotoxic
chemotherapies, which was already put into practice in the 1950s [123]. Nowadays, chemotherapeutic
combinations are still very effective treatments for various malignancies, such as childhood acute
lymphoblastic leukemia [124]. Over the years, many chemotherapeutic combinations have been
developed showing a potent antitumor effect through additive effects. However, synergistic
combinations of chemotherapeutics can be achieved when the DNA damaging mechanisms of
individual compounds can amplify each other. A notable example of a chemotherapeutic class that is
used in several successful chemotherapy combinations are antimetabolites [125,126]. By interfering
with nucleotide synthesis and their incorporation in newly synthesized DNA, these compounds
can inhibit the repair of DNA damage induced by other chemotherapeutics [125]. An example is
the introduction of a combination regimen containing oxaliplatin, irinotecan and the antimetabolite
5-FU (FOLFIRINOX) for the treatment of metastatic pancreatic cancer. Although this treatment was
unfortunately associated with increased toxicity, its development marks one of the most significant
steps forward in treating this malignancy up to this date [127].
Several years after the first chemotherapy combinations, the combination of radiotherapy and
chemotherapy was introduced in the clinic [128]. In addition to the fact that these regimens increased
antitumor efficacy as compared to radiotherapy alone for various cancers, they provide the opportunity
for spatial cooperation; while radiotherapy can be used for treatment of local tumors, systemic
chemotherapy can be used for (distant) metastases [129]. Similar to chemotherapy combinations,
DDR-mediated cellular responses to radiotherapy- and chemotherapy-induced DNA damage can
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interact in various ways, leading to potent combination therapies. One example is the combination of
cisplatin with radiotherapy, which is now successfully being used for treatment of, amongst others,
cervical cancer [130]. Cisplatin treatment leads to the formation of DNA adducts that can block repair
of nearby IR-induced DNA breaks, resulting in damage persistence and cell death [131]. Furthermore,
the effectiveness of antimetabolites in combination therapies has also been shown in combination with
radiotherapy. In this case, antimetabolites can inhibit repair of IR-induced DNA damage. For example,
5-FU is used in combination with radiotherapy for the treatment of gastrointestinal tumors [132].
Finally, the combination of different types of radiotherapy is commonly applied, with the
combination of EBRT and brachytherapy as a notable example. In the treatment of cervical cancer,
this regimen was shown to result in increased cancer-specific survival and overall survival as compared
to EBRT alone [133]. The use of brachytherapy in addition to EBRT has the advantage of delivering a
high local dose to the tumor specifically.
A challenge in developing radiotherapy or chemotherapy combinations is selecting the right
therapy timing and sequence, since this has implications for both efficacy and toxicity. It is important
to compare between concomitant versus sequential administration of multiple agents. For example,
combinations of radiotherapy and chemotherapy led to better patient outcome in locally advanced
non-small cell lung cancer when administered concomitantly, although this was associated with
increased toxicity as compared to sequential administration [134]. The most effective therapy
sequence strategy is highly dependent on the used agents, dose and specific disease indication
and thus requires optimization for specific cases. A second challenge is the identification of
biomarkers to select patients for specific combinations, which could be cancer-specific DDR defects.
As an example, combining temozolomide with radiotherapy for glioblastoma treatment led to
improved outcome as compared to radiotherapy alone, but only in tumors with a silenced gene
for MGMT [135]. The underlying mechanism is that MGMT is involved in the removal of DNA
alkylations by temozolomide. A functional MGMT protein might thus counteract the radiosensitization
by temozolomide by repairing temozolomide-induced DNA damage.
4.2. DDR Modulator Combinations
In addition to DDR modulator monotherapy treatments, of which efficacy mainly depends on
synthetic lethal relationships with cancer-specific DDR mutations, combinations with other DNA
damage-inducing therapies are actively being investigated [1]. Currently most data on DDR modulator
combination regimens is available for PARP inhibitors, but other compounds such as ATR inhibitors are
gaining increasing attention [136]. An important condition for these combination therapies is that the
DDR modulator impairs a pathway involved in repair of the induced DNA damage by radiotherapy
or chemotherapy, thereby leading to damage persistence and increase of cell death. Demonstrating
this concept, inhibitors of DNA-PK are investigated as a sensitizing agent for radiotherapy and
chemotherapy [137]. DNA-PK is an important player in NHEJ. Unfortunately, clinical trials of
combinations of DNA damaging therapies with DDR modulators resulted in unfavorable toxicity
profiles [1]. For example, combining PARP inhibitors with chemotherapy resulted in overlapping bone
marrow toxicity [138,139]. This underlines the necessity for more detailed insight in dosing and timing
schemes to allow further development.
Cancers that harbor DDR mutations might also benefit from targeting multiple DDR components:
for example, inhibition of ATR after PARP inhibitor therapy can overcome PARP inhibitor resistance in
tumors with a BRCA-mutant genetic background [140]. In addition, using multiple DDR modulators
can induce an artificial form of synthetic lethality in cancers without DDR mutations that can be
exploited by DDR modulator monotherapies: simultaneous application of multiple DDR modulators
can impair both a repair pathway and a back-up pathway at the same time [141]. In the absence of
specific DDR defects in the tumor, it is the intrinsically higher amount of DNA damage due to genomic
instability in cancer cells as compared to healthy cells that will result in a potentially acceptable
therapeutic window. The independence of these combinations on specific DDR mutations could
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make them applicable to a larger patient population than other DDR modulator-based therapies.
However, similar to combinations of DDR modulators with chemotherapy, a potential drawback of
combining multiple DDR modulators are the overlapping toxicity profiles, especially with regard
to bone marrow toxicity [142]. Thus, determining optimal dosing, timing and sequencing of these
combination therapies is crucial.
4.3. Immunotherapy Combinations
Few therapies in oncology have seen such tremendous development during the past two decades
as immunotherapy [143]. Nowadays immunotherapy is positioned as one of the major pillars of cancer
treatment, among surgery, radiotherapy and chemotherapy. Generally, this group of therapies works
by empowering the body’s own immune system to eradicate cancer cells. However, tumors employ
multiple cellular mechanisms to evade recognition and cell killing by immune system components, of
which one is the upregulation of immune checkpoint molecules that bind and inhibit adaptive immune
cells [144]. The application of antibodies against these molecules, called immune checkpoint inhibitors,
can significantly counteract this form of immune evasion [145].
DNA-damaging therapies have the ability to potentiate the immune response to kill cancer
cells [146,147]. Currently multiple clinical trials are running that investigate combinations of
immune checkpoint inhibitors with radiotherapy, chemotherapy and DDR modulators. Importantly,
treatment with DNA damaging agents can lead to immunogenic cell death, resulting in release of
tumor-specific antigens and, among other factors, danger-associated molecular pathogens (DAMPs) in
the environment [148]. Both these antigens and DAMPs can stimulate the adaptive immune response.
However, the relationship between tumor DNA damage, DNA damage repair and the immune system
is complex. Currently a wide variety of other potential mechanisms by which therapy-induced DNA
damage and repair influence the anticancer immune response are under investigation (reviewed
in [149]). An example is the activation of the stimulator of interferon genes pathway in the tumor
cell by cytosolic DNA fragments after DNA damage induction. This will lead to transcription of
pro-inflammatory interferon genes, stimulating the immune response [150].
In addition to investigating the mechanisms of immunogenicity of DNA damage-inducing
therapies, current research focuses on selection of suitable agents to combine with immunotherapy and
optimal dosing, sequence and timing [147]. Furthermore, identification of patient-specific biomarkers
to predict therapy efficacy for these combination regimens is a major focus point. Given the interplay
between DNA damage and repair and immunotherapy, cancer-specific DDR defects are currently
considered as potential valuable biomarkers [149].
5. Conclusions
DNA damage-inducing therapies have been of great importance for cancer treatment for decades.
The DDR is a crucial network in the cellular response to these therapies, guiding the decision between
repair of induced DNA lesions or induction of detrimental cellular fates such as cell death. Additionally,
the DDR plays a major role in both intrinsic and acquired therapy resistance. A large amount of
research efforts has led to an improved understanding of DNA damage-inducing drug properties and
the DDR pathways that mediate resulting cellular responses.
Currently a multitude of developments are predicting the important role for DNA
damage-inducing treatments in oncology to continue. Next to ongoing developments for the ‘classical’
therapies, radiotherapy and cytotoxic chemotherapy, the introduction of targeted drugs in oncology
has found its way into the field of DNA damage-inducing therapies through the development of DDR
modulators. Furthermore, combination therapies are an important future direction in oncology, as they
can increase anticancer efficacy of other treatments compared to monotherapy and lower the chance of
development of resistance. It is important to note that in some cases the pronounced cytotoxic effects
of radiotherapy and chemotherapy can be indispensable to achieve a potent and durable anticancer
response in combination therapies. Moreover, radiotherapy and cytotoxic chemotherapy are still
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a very effective first line treatment for a large variety of malignancies. It is therefore unlikely that
targeted therapies and other regimens such as immunotherapy will completely replace radiotherapy
and cytotoxic chemotherapy in the near future, but rather it is the careful selection, based on a
specific cancer genotype or phenotype, or combination of these modalities that is of great potential for
cancer treatment.
Important future challenges for DNA damage-inducing therapies include the further elucidation
of therapy mechanisms of action and crucial components of the DDR that mediate the cellular
response to therapy. A more detailed understanding of these properties can guide selection of DNA
damaging agents and treatment schemes for specific cancers. Notably, the improved understanding
of cellular therapy responses aids in the rational development of novel combination regimens of
DNA damage-inducing agents, potentially also with other therapy types such as immunotherapy.
This knowledge is also crucial for identifying biomarkers to guide patient selection for specific agents.
Although for DNA damaging agents these biomarkers are often DDR-based, other cellular factors
such as tumor proliferation rate might also play a role here. The identification of biomarkers not only
has the potential to personalize targeted therapies, but can also be used to refine radiotherapy and
chemotherapy. Ultimately, adaptation of treatment schemes to specific patients could lead to further
improvement of therapeutic windows.
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